| Document |
Document Title |
|
WO/2023/196629A1 |
The invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof; wherein Ra and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2- bridging moiety; A is -CH2- or -C(=O)-; T i...
|
|
WO/2023/196614A1 |
The disclosure provides compounds of Formulas (I), (I-2), (I-3), (I-4), (I-5), (II), (II-2), (II-3), (II-4), and (II-5) and pharmaceutically acceptable salts thereof. Also provided are compositions and methods of using the compounds, e.g...
|
|
WO/2023/196432A1 |
Disclosed herein, inter alia, are compounds of formula (I) and methods of use thereof for the modulation of certain chemokine receptor activity.
|
|
WO/2023/196291A1 |
The methods and compositions relate to the improvement of cell viability regarding in vitro differentiated cardiomyocytes. Addition of ROCK-inhibitors to pluripotent stem cells in combination with factors modulating differentiation pathw...
|
|
WO/2023/186691A1 |
The invention relates to substituted 2-C-azines of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing...
|
|
WO/2023/186294A1 |
The present invention relates to new forms of inhibitors of Axl/Mer receptor tyrosine kinase and CSF1R (colony stimulating factor 1 receptor), and in particular to new forms of N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl...
|
|
WO/2023/186126A1 |
The present invention relates to an aromatic ring compound and use thereof. Specifically provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable sal...
|
|
WO/2023/185752A1 |
Disclosed in the present invention are a triazolamide compound, a preparation method therefor, and a use thereof. Specifically, disclosed are a triazolamide compound as shown in formula I or a pharmaceutically acceptable salt thereof, an...
|
|
WO/2023/189602A1 |
A number of pest control agents have been used over the years. However, many of these pest control agents have various problems, for example, insufficient efficacy and limitation on the use thereof due to the occurrence of resistant pest...
|
|
WO/2023/184482A1 |
The present invention relates to a heterocyclic compound aminotriazinone derivative having general formula (I). The derivative has P2X3 receptor antagonistic activity, and particularly has selective and high antagonistic activity against...
|
|
WO/2023/184327A1 |
Provided herein are novel compounds, for example, compounds having a Formula I, Formula II-1 to II-7, Formula III-1 to III-9, IV, or V, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the comp...
|
|
WO/2023/185634A1 |
The present application relates to the field of medicine, and particularly discloses a compound of formula (I), a preparation method therefor, and use of said compound in the preparation of a drug for treating plasma kallikrein-mediated ...
|
|
WO/2023/192390A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2023/190015A1 |
In the production of crops in agriculture, horticulture, etc., damages caused by pests, etc., are still significant, and it has been required to develop a new agricultural and horticultural pesticide due to factors such as the emergence ...
|
|
WO/2023/187715A1 |
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B.
|
|
WO/2023/191468A1 |
The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegen...
|
|
WO/2023/185864A1 |
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that bin...
|
|
WO/2023/192416A1 |
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2023/190472A1 |
[Problem] To provide at least one selected from among a novel cyclohexylenediaminium salt, a production method therefor, a use thereof, and an MSE type zeolite obtained using same. [Solution] An MSE type zeolite having the X-ray powder d...
|
|
WO/2023/185920A1 |
Provided herein are FAK degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, dise...
|
|
WO/2023/191201A1 |
The present invention provides a novel pyrazole derivative compound represented by chemical formula I, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt ther...
|
|
WO/2023/192375A1 |
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
|
|
WO/2023/192578A1 |
The present invention relates to novel bifunctional compounds, as well as compositions thereof, which modulate KLHDC2 and/or function to recruit targeted proteins to KLHDC2 for degradation. These bifunctional compounds, which find utilit...
|
|
WO/2023/192348A1 |
Herein is disclosed a bioinspired approach in which triggered conformational changes are used to control electron transfer (ET) events. Photo-induced conformational rearrangements of a ligand are translated into changes in the coordinati...
|
|
WO/2023/185073A1 |
A poly(adenosine diphosphate-ribose)polymerase-7 (PARP7) inhibitor, and the use thereof in selectively inhibiting PARP7 activity or in treating or preventing diseases, disorders or conditions that are regulated by or affected by PARP7 ac...
|
|
WO/2023/187099A1 |
The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
|
|
WO/2023/192817A1 |
Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may ...
|
|
WO/2023/191666A1 |
The invention relates to the field of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form of 1-(2-(1H-imidazole-4-yl)-ethyl)piperidine-2,6-dione and to a pharmaceutical c...
|
|
WO/2023/185821A1 |
Disclosed is a 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound represented by formula (I). The compound can effectively inhibit the generation of 20-HETE, and has high activity, high selectivity and good ph...
|
|
WO/2023/185986A1 |
Disclosed herein is a compound of Formula (I) for inhibiting Bcl-xL and treating a disease associated with the undesirable Bcl-xL activity (Bcl-xL related diseases), a method of using the compounds disclosed herein for treating tumor or ...
|
|
WO/2023/185667A1 |
The present invention provides an HDAC11 subtype selective inhibitor, and a preparation method therefor and use thereof. The inhibitor of the present invention is an inhibitor having a structure represented by the following general formu...
|
|
WO/2023/192506A1 |
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
|
|
WO/2023/191469A1 |
The present invention relates to nitrogen-containing heterocyclic compounds having a phenyl group and uses thereof. The compounds, according to the present invention, effectively enhance synaptic plasticity without side-effects and thus ...
|
|
WO/2023/190286A1 |
A compound represented by formula (1) or a salt thereof, or an N-oxide thereof. [In formula (1), X1 represents an oxygen atom, a sulfur atom, NY1, or C(J5J6), n represents 0 or 1, J1-J4 each represent a hydrogen atom, a halogen atom, a (...
|
|
WO/2023/185791A1 |
A preparation method for a 2-aminopyridine derivative and an intermediate thereof, i.e., a preparation method for a compound shown in formula (VII) and an intermediate thereof. The method is mild in reaction conditions, simple to operate...
|
|
WO/2023/182899A1 |
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.
|
|
WO/2023/183520A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2023/180388A1 |
The present invention provides a series of 2,4- dioxotetrahydropyrimidinyl derivatives that bind cereblon, and their application as degrons in PROTACs. Androgen receptor PROTACs containing the 2,4-dioxotetrahydropyrimidinyl containing de...
|
|
WO/2023/180964A1 |
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...
|
|
WO/2023/183437A1 |
The present disclosure provides, in part, compounds of formula (I), wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, s...
|
|
WO/2023/183905A2 |
The present disclosure provides, inter alia, deuterated analogs of ulixertinib and pharmaceutically acceptable salts thereof, which are effective inhibitors of ERK protein kinases and have surprisingly improved pharmacokinetic and metabo...
|
|
WO/2023/180189A1 |
Disclosed are novel viral Mpro inhibitors according to Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to inhibit Mpro and...
|
|
WO/2023/178702A1 |
Provided in the present invention are a method for preparing lemborexant as represented by formula (I) and a method for preparing a lemborexant intermediate compound. According to the method for preparing lemborexant as represented by fo...
|
|
WO/2023/183652A1 |
The present invention relates to compounds and methods useful for dual inhibition of C-X-C receptor type 4 (CXCR4) and Bruton's tyrosine kinase (BTK). The invention also provides pharmaceutically acceptable compositions comprising compou...
|
|
WO/2023/183601A1 |
This disclosure features methods for preparing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that inhibit epidermal growth factor receptor (EGFR, E...
|
|
WO/2023/178693A1 |
Provided in the present invention is a method for preparing lemborexant, which method comprises the following steps: subjecting compound II and compound III as raw materials to a reaction in a second reaction solvent to obtain lemborexan...
|
|
WO/2023/179793A1 |
A crystal form of a 1H-pyrrolo[2,3-c]pyridine compound and a preparation method therefor. Also provided is a use of compound (II) and a crystal form thereof in the preparation of a drug for treating related diseases.
|
|
WO/2023/183919A1 |
Described herein are compounds of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as IKZF2 degraders) in treating or preventing diseases or disorders.
|
|
WO/2023/182754A1 |
The present invention relates to an organic compound that can enhance the light efficiency of light extracted to the outside of an organic light-emitting element due to having a low refractive index, and thus can be effectively utilized ...
|
|
WO/2023/179205A1 |
Provided are a diimide derivative, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than th...
|
